CTOs on the Move

Vero Biotech

www.vero-biotech.com

 
Inhaled nitric oxide has the potential to benefit patients, with a range of cardiopulmonary conditions including COVID-19 Coronavirus.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Vero Biotech raised $50M on 01/20/2021

Similar Companies

Cassini Technologies

Driven by curiosity and love of science Cassini has been dedicated to push the boundaries of corneal diagnostics solutions ✓ Advised by top surgeons

Centaur Pharmaceuticals

Centaur Pharmaceuticals is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Blood and Cell Technologies

A global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections. Terumo BCT believes in the potential of blood to do even more for patients than it does today.

Stone and Magnanini

Stone and Magnanini is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea`s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea`s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company`s pipeline through global partnering and commercialization efforts.